ArticleStem cell research & therapy2025
Mesenchymal stem cells-derived exosomes and Kaempferol improve myelin repair via attenuating inflammation and oxidative stress in a cuprizone-induced demyelination model.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mesenchymal stem/stromal cell-based therapies for autism spectrum disorder: emerging evidence and clinical prospects.Journal of translational medicine · 2026Review
- Natural flavonoids in multiple sclerosis: molecular insights and emerging therapeutic strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundExosomes (EXOs), small vesicles secreted by cells, and kaempferol (KMP) as a natural flavonoid have anti-inflammatory and anti-oxidant activities. Here, we investigated the therapeutic potential of combination therapy of mesenchymal stem cell (MSC)-derived EXOs with KMP in a cuprizone (CPZ)-induced demyelination model.
methodsForty-five male C57BL/6J mice were used in this study. KMP was administered intracerebroventricularly and EXOs were delivered intranasally. Behavioral tests, tissue analyses, and molecular assays measured working memory, cognitive function, motor function, myelin integrity, oxidative stress, and inflammation.
resultsBehavioral assessments using Y-maze, novel arm discrimination, and wire hang tests revealed that the combination therapy significantly improved working memory, spatial recognition, and motor endurance compared to KMP or EXOs treated groups. Histological analyses demonstrated marked prevention of demyelination, as evidenced by enhanced myelin integrity on FluoroMyelin and Black-Gold II staining. At the molecular level, the combined treatment up regulated the antioxidant genes expression and regulated the activity of key antioxidant enzymes, while simultaneously reducing lipid peroxidation. Glial activation and pro-inflammatory cytokine genes expression were also reduced in the EXO + KMP treated mice.
conclusionsThese findings suggest that combination therapy with EXOs and KMP improves myelin repair by targeting oxidative stress and neuroinflammation in a CPZ-induced demyelination model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.